Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Alzheimer Disease
Clinical trial register · South Korea

Alzheimer Disease Trials in South Korea, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3361 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:17 UTC
3361
Studies in scope
all four open statuses
1828
Recruiting now
open to new participants
499
Lead sponsors
across recruiting studies
Top sites
Seoul 8 Incheon 4 Cheonan 2 Seongnam-si 2 Gwangju 2
Narrow the registerReset
Recruitment status
Phase
Site location
Seoul8 Incheon4 Cheonan2 Seongnam-si2 Gwangju2
All 17 locations
Target enrolment
to

Alzheimer Disease trials in South Korea

10 of 3361 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
ReadyCure Inc.
Not applicable
30
Cheonan
2026-10-26
By invitation
NVP Healthcare
Not applicable
60
Seoul
2026-01-20
Recruiting
Bristol-Myers Squibb
Phase 3
650
Incheon, Seoul, Deagu
2025-12-02
Not yet open
BeyondBio Inc.
Phase 2
90
Seoul
2025-07
Recruiting
Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)
NCT06889818Mild Cognitive Impairment, Dementia, Subjective Cognitive Decline (SCD), Alzheimer Disease
Ewha Womans University Mokdong Hospital
Observational
4,000
Incheon, Seoul
2025-02-24
Recruiting
BnH Research
Phase 1
92
Seoul
2024-10-22
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Ansan-si, Yongin-si, Seoul, Yeongdeungpo-gu, Gangwon-do
2024-09-26
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Seongnam-si, Gwangju, Seoul, Chuncheon, Incheon, Cheonan, Daegu, Guri-si
2022-12-23
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,500
Busan, Guri-si, Gwangju, Incheon, Junggu, Namdong-gu, Seongnam, Seongnam-si
2022-10-10
Active, closed
Seoul National University Hospital
Observational
640
Seoul
2022-01-01
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-south-korea/condition/alzheimer-disease

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,361 studies in total at the last sync on 08 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Alzheimer Disease.

How many Alzheimer Disease trials are recruiting in South Korea?

5 of the 10 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Alzheimer Disease), 10 studies
PhaseStudiesRecruitingShare
Phase 34240%
Not applicable2120%
Observational2120%
Phase 11110%
Phase 21010%

Most active sponsors

Lead sponsors with the most studies (Alzheimer Disease)
Lead sponsorStudiesRecruiting
AriBio Co., Ltd.10
BeyondBio Inc.10
BnH Research11
Bristol-Myers Squibb11
Eli Lilly and Company10
Ewha Womans University Mokdong Hospital11
Karuna Therapeutics, Inc., a Bristol Myers Squibb company11
NVP Healthcare10
ReadyCure Inc.11
Seoul National University Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.